Fixed-dose combinations containing stavudine have played a critical role in the worldwide scale-up of antiretroviral therapy, but increasing concern exists regarding adverse events due to mitochondrial toxicity. We describe the first reported occurrence of lactic acidosis within a family of 3 HIV-infected individuals. This report is only the second of lactic acidosis affecting an African child. Further research is indicated to identify possible genetic and other risk factors underlying mitochondrial toxicity in African populations, especially among pediatric cohorts.
Introduction
Remarkable progress has been made in the treatment of HIV infection in resource-limited settings. Four million adults and children were receiving antiretroviral therapy (ART) in lowand middle-income countries as of December 2008. 1 This scale-up has been made possible in large part by the availability of affordable fixed-dose combinations consisting of nevirapine (NVP), stavudine (d4T), and lamivudine (3TC).
Recently, more attention has been directed toward the long-term toxicity of d4T, which threatens the sustainability of treatment efforts. [2] [3] [4] Among African adults, d4T has been associated with high rates of peripheral neuropathy, lipodystrophy, and lactic acidosis. For this reason, the World Health Organization (WHO) has recommended that national programs move away from the use of this agent whenever possible. 5 Less is known about the tolerability of d4T among African children. Data from Western children and adolescents demonstrate that this population is also susceptible to mitochondrial toxicity, including lipodystrophy and lactic acidosis. [6] [7] [8] [9] These same adverse effects have been observed in populations in Brazil, 10 Thailand, 11 and India. 12 In resource-limited settings, fixed-dose combinations are usually split and administered to children weighing less than 30 kg according to a standard protocol. If these children develop regimen-limiting toxicity to d4T, little guidance is available for the use of alternative fixed-dose combinations.
We describe a family composed of 3 individuals (2 parents and 1 child) who developed lactic acidosis while receiving d4T. To our knowledge, this report is the first description in the peerreviewed medical literature of such an occurrence in a multigenerational family and only the second report describing lactic acidosis in an African child. 13 
Methods
Partners in Hope Medical Center, located in Lilongwe, Malawi, is a nongovernmental organization providing HIV care and treatment with the support of the Malawi National AIDS Commission, external donors, and income generated by private medical services. Facilities for measuring plasma lactate are available (Ektachem DT60; Kodak, Rochester, New York, USA). A family of 3 individuals (2 parents and 1 child) was identified to have elevated lactate levels at different points during the treatment with d4T-containing ART. Information for each patient was extracted using a standardized data collection tool.
Written permission was obtained from the family to publish this report.
Case Reports
The following case reports describe 2 parents (biologically unrelated father and mother) and their biological daughter.
Patient 1
A 34-year-old male was diagnosed HIV positive in 2006. Relevant past medical history included treatment of pulmonary tuberculosis in 2003. In May 2007, the CD4 count was 140 cells/mm 3 and the weight was 52 kg. ART was begun with a standard fixed-dose combination of NVP (200 mg), d4T (30 mg), and 3TC (150 mg). In March 2008, the patient presented with 1 week of emesis, anorexia, weakness, generalized body pain, and abdominal fullness. The vital signs were within normal limits. He appeared ill and the skin was noted to be dry, but otherwise the physical examination was unremarkable. The initial lactate concentration was 2.4 mmol/L and the alanine aminotransferase (ALT) level was 89 u/L. Testing for hepatitis B antigen was not preformed. Promethazine and magnesium trisilicate were prescribed. ART was continued.
The following month symptoms of nausea, weakness, and loss of appetite persisted. The lactate concentration was 4.4 mmol/L. ART was discontinued and intravenous fluid administered. One month later, the lactate measurement had declined to 2.0 mmol/L. The patient was observed off ART. In July 2008, the lactate concentration remained 2.0 mmol/L. Alternative first-line ART was initiated with a fixed-dose combination of NVP, 3TC, and zidovudine ([ZDV] 300 mg). Twenty months after switching to alternative first-line therapy the CD4 count was 266 cells/mm 3 , and the patient was clinically well.
Patient 2
A 29-year-old female was diagnosed HIV positive in March 2006. She had oral candidiasis and prolonged fever and diarrhea. Baseline CD4 measurement yielded 45 cells/mm 3 . The weight was 50 kg, at the time ART was initiated with a standard fixed-dose combination of NVP, d4T (30 mg), and 3TC in April 2006. The CD4 count rose to 316 cells/mm 3 10 months later. In May 2007, the patient presented with a 2-week history of bilateral lower extremity swelling, anorexia, and nausea. The weight was 62 kg (body mass index 23). She appeared ill with stable vital signs. There was pitting edema of both feet. Measured lactate was 5.1 mmol/L. ART was discontinued and the patient was told to increase fluid intake. Nine days later, the lactate level had risen to 7.9 mmol/L. After 1 month, the concentration had decreased to 4.3 mmol/L. The patient continued to experience weakness, anorexia, and weight loss. Measurements of aspartate aminotransferase (AST) and ALT were 859 and 231 u/L, respectively. A test for hepatitis B surface antigen was positive.
The concentration of lactate eventually declined to 2.3 mmol/L in August 2007, when the patient reinitiated antiretroviral drugs with alternative first-line therapy consisting of NVP, ZDV, and 3TC. By February 2009, the CD4 count had fallen to 231 cells/mm 3 . A viral load measurement performed in June 2009 yielded 9731 copies/mL. ART was changed to the standard national second-line regimen consisting of lopinavir/ritonavir (LPV/r), tenofovir (TDF), ZDV, and 3TC. Nine months later, the patient was alive and clinically well. The CD4 count had risen to 547 cells/mm 3 .
Patient 3
A 4-year-old female was diagnosed HIV positive in March 2006. She had experienced recurrent pneumonia and was later treated for pulmonary tuberculosis in 2007. Baseline CD4 measurement was 193 cells/mm 3 (CD4 percentage 12%). In April 2006, when the weight was 9.7 kg, ART was begun according to national protocol by splitting tablets of the standard fixeddose combination of NVP, d4T, and 3TC (one-half tablet in the morning and one-fourth tablet in the evening). In May 2008, her weight was 16.8 kg. The child was receiving split tablets of fixed-dose NVP, d4T (30 mg), and 3TC per national guidelines (three-fourth tablet in the morning and one-half tablet in the evening). Nausea, emesis, anorexia, and weakness developed over a 1-week period. The child appeared ill but was afebrile. Physical examination was otherwise unrevealing. Measurement of plasma lactate revealed a value of 5.3 mmol/L. ART was discontinued. One month later, the concentration was still 5.2 mmol/L. Amoxicillin-clavulanic acid was given for a respiratory infection.
In July 2008, the concentration of lactic acid had declined to 1.6 mmol/L. The hematocrit was 45%. In December 2008, when the child weighed 18.6 kg, alternative first-line therapy was begun with NVP 200 mg (three-fourth tablet in the morning and one-half tablet in the evening per national protocol) and a fixed-dose combination of ZDV 300 mg and 3TC 150 mg (one-half tablet twice per day). In March 2009, the CD4 count had risen to 991 cells/mm 3 . In July 2009, a fixed-dose combination of NVP, ZDV, and 3TC became available. Initially, three-fourth tablet was administered twice per day, but in September 2009, when her weight was 19.5 kg and height 118 cm, analysis according to weight and body surface area (data not shown) prompted a change in dosing to three-fourth tablet in the morning and one-half tablet in the evening. The hematocrit was 40%. Six months later, the child was healthy and tolerating ART. The CD4 count was 988 cells/mm 3 .
Discussion
We document for the first time the unusual scenario of a multigenerational family consisting of 2 biologically unrelated parents and 1 biological child presenting with d4T-induced lactic acidosis. Risk factors for d4T toxicity include low baseline CD4 count, 14 obesity (in the case of lactic acidosis), 4 and use of concomitant medications known to cause peripheral neuropathy (such as isoniazid). 15 Less well studied are the genetic factors contributing to these adverse effects. A novel mutation in the enzyme DNA-g polymerase has been linked with lactic acidosis. 16 A study from Indonesia found that, in addition to increasing age and height, the allele TNFA-1031*2 was associated with a higher risk of developing peripheral neuropathy, suggesting a possible heritable predisposition to d4T toxicity. 17 Given the importance of this affordable agent to the worldwide HIV treatment effort, its near ubiquity within national ART programs, and the high rates of toxicity observed in African populations, further research investigating the contribution of genetic factors is warranted. The consequences of intolerance to first-line therapy have been significant for this family. The father, mother, and child were forced to switch from the widely available first-line fixed-dose combination after 48, 57, and 107 weeks, respectively. In a report from South Africa, the median time on d4T prior to the development of lactic acidosis was 34 weeks (range 17-76). 4 Prolonged delay in reinitiating ART (Table 1) while awaiting resolution of lactic acidosis can compromise immune function and increase susceptibility to opportunistic infections. Patient 2 (the mother) was changed to second-line treatment after virological failure of the first-line regimen. Interruption of fixed-dose combinations predicts resistance and treatment failure, 18 especially when nucleoside reverse transcriptase inhibitors cannot be continued to ''cover the tail'' of exposure to what is essentially NVP monotherapy.
Lactic acidosis, including cases leading to death, has been described in Western cohorts of HIV-infected children and adolescents. 8, 19, 20 Although the true incidence is unknown, it is generally believed that the rate is lower than that found in adults. The nature of the HIV epidemic in Africa and other resourcelimited settings means that large numbers of children are now being exposed to this agent. Each year 420 000 new pediatric infections occur worldwide. Of the 2.5 million children living with HIV globally, 90% live in sub-Saharan Africa. 21 An abstract from a pediatric HIV clinic in Malawi describes 4 cases of lactic acidosis from among a cohort of 1434 children receiving d4T-containing ART over a median period of 1.3 years. 13 In summary, we describe a multigenerational family, the members of which each experienced episodes of d4T-induced lactic acidosis. Management of this complication in children is particularly challenging given the lack of access to individual alternative drugs that can be dosed specifically according to weight and body size. Further research is needed to determine risk factors (including possible genetic mechanisms) for lactic acidosis in African populations and the incidence of d4T toxicity in African pediatric cohorts.
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